


Appl. No.: 10/672,613
 Amendment dated January 19, 2005
 Reply to Office Action of October 20, 2004

Amendments to the Claims:

1. (Currently amended) A compound of the formula I



in which

R¹ is selected from:

- a) CONR⁵R⁶, in which R⁵ and R⁶ independently of one another are H or C₁-C₆-alkyl or, together with the nitrogen atom to which they are bonded, form a saturated heterocyclic radical having 5 or 6 ring atoms and one or two heteroatoms which independently of one another are selected from N and O;
- b) A-CONR⁵R⁶, in which A is C₁-C₆-alkylene which is optionally substituted by C₁-C₃-alkyl-CO, and R⁵ and R⁶ independently of one another are H, C₁-C₆-alkyl or phenyl which is optionally substituted by one or 2 halogen atoms;
- c) C₁-C₆-alkylene-R⁷, where R⁷ is NR⁵R⁶, an aromatic heterocyclic radical having 5 or 6 ring atoms and one or two heteroatoms, which independently of one another are selected from N, S and O, where the heterocyclic radical can optionally be fused to a benzene ring, or is COOR⁸, wherein R⁵ and R⁶ independently of one another are H or C₁-C₆-alkyl and R⁸ is H or C₁-C₆-alkyl;
- d) C₁-C₆-alkylene-CO-R⁹, where R⁹ is phenyl which is optionally substituted by halogen;
- e) C₁-C₆-alkylene-NR¹⁰-CO-R¹¹, or
- f) C₁-C₆-alkylene-NR¹⁰-SO²-R¹²,

2 of 10

RTA01/2173134v1

Appl. No.: 10/672,613
Amendment dated January 19, 2005
Reply to Office Action of October 20, 2004

R^{10} is H or C_1 - C_6 -alkyl,

R^{11} is

- phenyl which is optionally substituted by 1, 2 or 3 substituents, which independently of one another are selected from halogen, CN, NO_2 , CF_3 , OC_1 - C_6 -alkyl and C_1 - C_6 -alkyl,
- naphthyl,
- C_1 - C_6 -alkyl which is optionally substituted by 1 or 2 phenyl groups,
- C_2 - C_6 -alkenyl,
- $CH=CH$ -phenyl, or
- ~~— an aromatic, heterocyclic radical having 5 or 6 ring atoms and 1 or 2 heteroatoms, which independently of one another are selected from N, O or S, or~~
- NR^5R^6 , where R^5 and R^6 independently of one another are H or C_1 - C_6 -alkyl;

R^{12} is

- phenyl which optionally has 1, 2 or 3 substituents which independently of one another are selected from halogen, NO_2 , CF_3 , OC_1 - C_6 -alkyl, C_1 - C_6 -alkyl, NH_2 and $NHCOC_1$ - C_3 -alkyl,
- C_1 - C_6 -alkyl which is optionally substituted by one or two phenyl groups,
- or
- naphthyl,

R^2 is H, C_1 - C_6 -alkyl or $(CH_2)_6COOH$,

R^3 and R^4 , which can be identical or different, are H, OH, OC_1 - C_6 -alkyl, halogen or C_1 - C_6 -alkyl which is substituted by 1, 2 or 3 halogen atoms, where at least one of the radicals R^3 and R^4 is OH or OC_1 - C_6 -alkyl,

3 of 10

RTA01/2173134v1

Appl. No.: 10/672,613
Amendment dated January 19, 2005
Reply to Office Action of October 20, 2004

n is 0, 1 or 2 and

o is 0, 1, 2, 3 or 4,

and the optical isomers and physiologically tolerable salts thereof.

2. (Currently amended) A compound as claimed in claim 1, where R^1 is selected from:

- a) CONR^5R^6 , in which R^5 and R^6 independently of one another are H or $\text{C}_1\text{-C}_6$ -alkyl or, together with the nitrogen atom to which they are bonded, form a saturated heterocyclic radical having 5 or 6 ring atoms and one or two heteroatoms which independently of one another are selected from N and O;
- b) $\text{A-CONR}^5\text{R}^6$, in which A is $\text{C}_1\text{-C}_6$ -alkylene which is optionally substituted by $\text{C}_1\text{-C}_3$ -alkyl-CO, and R^5 and R^6 independently of one another are H, $\text{C}_1\text{-C}_6$ -alkyl or phenyl which is optionally substituted by one or 2 halogen atoms;
- c) $\text{C}_1\text{-C}_6$ -alkylene-CO- R^9 , where R^9 is phenyl which is optionally substituted by halogen;
- d) $\text{C}_1\text{-C}_6$ -alkylene-NR¹⁰-CO- R^{11} ;
- e) $\text{C}_1\text{-C}_6$ -alkylene-NR¹⁰-SO²- R^{12} ,

R^{11} is naphthyl, $\text{C}_2\text{-C}_6$ -alkenyl, or $\text{CH}=\text{CH}$ -phenyl or an aromatic, heterocyclic radical having 5 ring atoms and 1 or 2 heteroatoms, which independently of one another are selected from N, O or S.

and R^2 , R^3 , R^4 , R^{10} and R^{12} have the meaning as indicated in claim 1.

3. (Original) A compound as claimed in claim 1, where both radicals R^3 and R^4 are a $\text{C}_1\text{-C}_6$ -alkoxy group.

Appl. No.: 10/672,613
Amendment dated January 19, 2005
Reply to Office Action of October 20, 2004

4. (Original) A compound as claimed in claim 1, where R^1 is $CONR^5R^6$ and R^5 and R^6 have the meanings indicated in claim 1.

5. (Original) A compound as claimed in claim 1, where R^1 is $A-CONR^5R^6$ and A, R^5 and R^6 have the meanings indicated in claim 1.

6. (Original) A compound as claimed in claim 1, where R^1 is C_1-C_6 -alkylene-CO- R^9 , in which R^9 is phenyl which is optionally substituted by halogen.

7. (Currently amended) A compound as claimed in claim 1, where R^1 is C_1-C_6 -alkylene- R^7 , in which R^7 is pyridyl, in particular 3-pyridyl or 4-pyridyl, quinolyl or benzimidazolyl NR^5R^6 , and R^5 and R^6 have the meanings indicated in claim 1.

8. (Canceled)

9. (Original) A compound as claimed in claim 1, where R^1 is C_1-C_6 -alkylene-NR¹⁰-CO- R^{11} , in which R^{10} is H or C_1-C_6 -alkyl and R^{11} is phenyl which is optionally substituted by 1, 2 or 3 substituents, which independently of one another are selected from halogen, CN, NO₂, CF₃, OC_{1-C6}-alkyl and C_{1-C6}-alkyl.

10. (Original) A compound as claimed in claim 9, where R^1 is C_1 -, C_2 - or C_3 -alkylene-NR¹⁰-CO- R^{11} , in which R^{10} is H or C_1-C_4 -alkyl and R^{11} has the meanings indicated in claim 9.

11. (Original) A compound as claimed in claim 1, where R^1 is C_1-C_6 -alkylene-NR¹⁰-SO²- R^{12} , in which R^{10} and R^{12} have the meanings indicated in claim 1.

12. (Currently amended) A compound as claimed in claim 1, where R^{12} is naphthyl or phenyl which has 1, 2 or 3 substituents, which independently of one another are selected from halogen, NO₂, CF₃, OC_{1-C6}-alkyl, C_{1-C6}-alkyl, NH₂ and NHCOC_{1-C3}-alkyl.

5 of 10

RTA01/2173134v1

Appl. No.: 10/672,613
Amendment dated January 19, 2005
Reply to Office Action of October 20, 2004

13. (Original) A compound as claimed in claim 11, where R^{12} is C_1 - C_6 -alkyl which is optionally substituted by one or two phenyl groups.

14. (Original) A compound as claimed in claim 1, where R^1 is C_1 - C_6 -alkylene- NR^{10} - $CO-R^{11}$, in which R^{10} is H or C_1 - C_4 -alkyl and R^{11} is C_1 - C_6 -alkyl which is optionally substituted by one or two phenyl groups, or is $-CH=CH$ -phenyl.

15. (Original) A compound as claimed in claim 14, where R^1 is C_1 -, C_2 - or C_3 -alkylene- NR^{10} - $CO-R^{11}$, in which R^{10} and R^{11} have the meanings indicated in claim 14.

16. (Currently amended) A compound as claimed in claim 1, where R^1 is C_1 - C_6 -alkylene- NR^{10} - $CO-R^{11}$, in which R^{11} is naphthyl or an aromatic, heterocyclic radical having 5 ring atoms and 1 or 2 heteroatoms, which independently of one another are selected from N, O or S and R^{10} is H or C_1 - C_n -alkyl.

17. (Canceled)

18. (Original) A compound as claimed in claim 1, where R^1 is C_2 -alkylene- NR^{10} - $CO-R^{11}$, in which R^{11} is NR^5R^6 and R^5 and R^6 independently of one another are C_1 - C_6 -alkyl.

19. (Currently amended) A compound as claimed in claim 1, where R^1 is C_1 - C_6 -alkylene- R^7 , in which R^7 is 2-pyridyl or $COOR^8$ and R^8 is H or C_1 - C_6 -alkyl.

20. (Original) A pharmaceutical or cosmetic composition comprising at least one compound as claimed in claim 1, together with one or more pharmaceutically acceptable vehicles or additives.

Appl. No.: 10/672,613
Amendment dated January 19, 2005
Reply to Office Action of October 20, 2004

21. (Original) A method for treating a disease that is connected with an immune system disorder, comprising administering a pharmaceutical composition comprising at least one compound as claimed in claim 1.

22. (Original) A method for treating inflammation, comprising topically applying a pharmaceutical composition comprising at least one compound as claimed in claim 1.

23. (Original) A procedure for the treatment of diseases which are connected with a disorder of the immune system, where an amount of a compound as claimed in claim 1 having an immunomodulating or cyclooxygenase-inhibiting action is administered to a person who needs treatment of this type.